Clinical Trial Update: Avelumab in G2-3 NET [Phase 2]

View source ↗

Summary

A Phase 2 trial of avelumab in patients with grade 2-3 neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED